03 August 2018
Visiongain’ has launched a new pharma report Global Neurovascular Devices Market Forecast to 2027: Cerebral Embolization and Aneurysm Coiling Devices, Cerebral Angioplasty and Stenting Systems, Support Devices, Neurothrombectomy Devices
The neurovascular devices market is segmented into Cerebral Embolization and Aneurysm Coiling Devices, Cerebral Angioplasty and Stenting Systems, Support Devices, and Neurothrombectomy Devices. The market includes products such as clot retrieval devices, microcatheters, guidewires, stent retrievers, aspiration systems, etc.
The lead analyst of the report commented “The neurovascular devices market is driven by aging population, high incidence of obesity, increasing demand for minimally invasive procedures, and growing awareness of neurovascular diseases. In addition, technological advancements to develop new devices will further drive the market growth. The weaknesses of the market include high cost of devices and disadvantages of neurovascular devices.
However, increasing healthcare expenditures to provide better facilities and automated products showcase growing opportunities for the market growth. High cost of R&D activities and alternative medication therapies pose a major threat to the neurovascular devices market.”
Leading companies featured in the report include Stryker Corporation, Medtronic
Johnson & Johnson, Terumo, Penumbra.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
For the companies operating in the global influenza vaccines market, there is an immense opportunity from emerging economies across the globe.
30 September 2020
Maintaining the quality and safety of the product in the supply chain has always been a high priority for pharmaceutical companies. New market dynamics including an evolving product line, more stringent regulations, geographically connected supply chains, rising risk, and extreme cost pressure have raised stakes significantly.
28 September 2020
The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.
23 September 2020
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.